Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 658
- Registration Number
- NCT01865747
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 32
- Registration Number
- NCT01761773
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
- Conditions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Exelixis
- Registration Number
- NCT01683110
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1028
- Registration Number
- NCT01605227
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 85
- Registration Number
- NCT01553656
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Ariake, Koto, Japan
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 119
- Registration Number
- NCT01522443
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 26
- Registration Number
- NCT01493869
- Locations
- 🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 40
- Registration Number
- NCT01100619
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 19
- Registration Number
- NCT01068782
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 26
- Registration Number
- NCT00960492
- Locations
- 🇺🇸
University of Virginia Health System/Division of Neuro-Oncology, Charlottesville, Virginia, United States
🇺🇸Duke University Medical Center; The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States